Back to Quality of Life Measurement - HOME

Children's Dermatology Life Quality Index

INFORMATION & CONDITIONS CONCERNING USE


COPYRIGHT

The CDLQI is copyright world-wide and can only be reproduced with permission from the authors.

The USA Library of Congress Registration

Number: TXU 620272
Registration Date: 7 February 1994

Authors

Dr M S Lewis-Jones and Professor A Y Finlay

The copyright statement

Children's Dermatology Life Quality Index. M S Lewis-Jones,A Y Finlay, May 1993. This must not be copied without the permission of the authors. The copyright statement must always be reproduced at the end of every copy of these questionnaires in whatever language.

PERMISSION

There is a simple method for getting formal permission for use of the CDLQI. Please contact Professor A Y Finlay or Dr M S Lewis-Jones directly at the addresses given below. Formal permission is usually  given immediately.

WHERE TO GET FURTHER INFORMATION

Please contact:

Professor Andrew Y Finlay
Department of Dermatology
Wales College of Medicine, Cardiff University
Heath Park, CARDIFF CF14 4XN
Wales, United Kingdom

Telephone: + 44 (0)29 20744721
Fax: + 44 (0)29 20744312
e-mail: finlayay@cf.ac.uk

Dr M S Lewis-Jones
Consultant Dermatologist
Ninewells Hospital & Medical School
Department of Dermatology
DUNDEE, Tayside DD1 9SY
Scotland, United Kingdom

Telephone: + 44 (0)1382 660111
Fax: + 44 (0)1382 660445
e-mail: sue.lewis-jones@nhs.net

There are over 55 publications describing the use of the CDLQI world-wide. An updated version of this list is available from HERE.

TRANSLATIONS

There are translations of the CDLQI in the following languages:-

Arabic, Czech, Danish, English(UK), English(US), Finnish, French, German, Hungarian, Italian, Polish, Portuguese, Portuguese (Brazilian), Spanish (American), Spanish (European), Swedish, Cantonese, Dutch, Japanese, Romanian, Ukranian, Norwegian, Taiwanese, Turkish.

Cartoon versions:
Dutch, English, French, Japanese, Spanish (American)

If it is required to make a further translation of these Indexes into other languages it is essential that validated translations be used. At the very minimum this requires two independent translators translating the measures from English into the alternative language. These two translators then discuss their translations and agree on a single translation in the alternate language. At this stage a third and fourth translator are asked to independently back-translate the alternate language version into English. At this stage the back-translations need to be reviewed by the copyright holders. Nearly always small problems become apparent at this stage and it is necessary for further changes to be made in the alternative language translation. This then needs to be validated by a further process of back-translation. Advice on this process can be gained from the address below.

Please note that the copyright for any translation is retained by the original copyright holders and is not transferred or shared with any additional copyright holders even though they may have been involved in the translation.

CHARGES

There is a small charge for the use of the CDLQI. This charge is based upon the total number of patients to whom the Index is administered. It is not based upon the frequency with which the questionnaires are administered to each individual patient.

These charges are always waived by the copyright holders for non-funded 'academic' studies and they are mainly applied to pharmaceutical companies using these Indexes in Phase II and Phase III studies. Please contact the authors concerning this. The charge per patient is as follows:

UK: 5.00 USA and rest of world: $9.50 (Plus exchange rate at the time of invoicing)
CDLQI: 50% of the payment should be made by cheque as per invoice from the Wales College of Medicine, Cardiff University.
50% of the payment should be made by cheque to the following account 'Tayside Dermatology Research Fund' and sent to Dr M S Lewis-Jones at the address above.

INSTRUCTIONS FOR USE

CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX (CDLQI)

The Children's Dermatology Life Quality Index questionnaire is designed for use in children, i.e. patients from age 5 to age 16. It is self explanatory and can be simply handed to the patient who is asked to fill it in with the help of the child's parent or guardian. It is usually completed in one to two minutes.

Scoring

The scoring of each question is as follows:
Very much
A lot
A little
Not at all
Question unanswered
Question 7: "prevented school"
scored 3
scored 2
scored 1
scored 0
scored 0
scored 3

The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The CDLQI can also be expressed as a percentage of the maximum possible score of 30.

Detailed analysis of the CDLQI

The CDLQI can be analysed under six headings as follows:
Symptoms and feelings
Leisure
School or holidays
Personal Relationships
Sleep
Treatment
Questions 1 and 2
Questions 4, 5 and 6
Questions 7
Question 3 and 8
Questions 9
Question 10
Score maximum 6
Score maximum 9
Score maximum 3
Score maximum 6
Score maximum 3
Score maximum 3

The scores for each of these sections can also be expressed as a percentage of either 9, 6 or 3.

Interpretation of incorrectly completed questionnaires

  1. If one question is left unanswered this is scored 0 and the scores are summed and expressed as usual out of a maximum of 30.
  2. If two or more questions are left unanswered the questionnaire is not scored.
  3. If both question 7a and 7b are completed the higher of the two scores should be counted.

Reference

Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): Initial validation and practical use. British Journal of Dermatology, 1995; 132: 942-949.

Cartoon Version of CDQLI

The cartoon version is detailed in the following article:

Holme SA, Man I, Sharpe SL, Dykes PS, Lewis-Jones MS, Finlay AY. "The Children's Dermatology Life Quality Index: Validation of the Cartoon Version". British Journal of Dermatology 2003; 148: 285-290.

Click here for a printable PDF version of this document.